Primary Lung Adenocarcinoma With 68Gallium Prostate-Specific Membrane Antigen-PET/CT Scan Avidity in a Patient on Surveillance After Prostatectomy

Chia, Jun Yang; Loi, Hoi Yin; Khor, Lih Kin; Lee, King Chien Joe; Seow, Yi Heng

doi:10.1016/j.clgc.2018.03.009

Cited by 8 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is usually classified in two histological groups, small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), which includes adenocarcinoma, squamous cell carcinoma and large cell carcinoma, each one with a specific sub-classification [ 66 ]. Since PCa and lung cancer are the most frequent tumors in men, several case reports in the literature have described the incidental detection of positive lung findings on 68 Ga-PSMA PET/CT conducted in patients with PCa, which were confirmed to be primary lung cancers based on the histology results [ 67 , 68 , 69 , 70 ] ( Figure 3 ).…”

Section: Lung Cancermentioning

confidence: 99%

PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?

Lauri¹,

Chiurchioni²,

Russo³

et al. 2022

JCM

View full text Add to dashboard Cite

In the past decades, the expanding use of prostate-specific membrane antigen (PSMA) imaging for prostate cancer has led to the incidental detection of a lot of extra-prostatic malignancies showing an increased uptake of PSMA. Due to these incidental findings, the increasing amount of immunohistochemistry studies and the deeper knowledge of the mechanisms of expression of this antigen, it is now clear that “PSMA” is a misnomer, since it is not specific to the prostate gland. Nevertheless, this lack of specificity could represent an interesting opportunity to bring new insights on the biology of PSMA and its sites of expression to image and treat new conditions, particularly several cancers. In this review, we will describe the main extra-prostatic cancers that exhibit PSMA expression and that can be studied with PSMA-based positron emission tomography–computed tomography (PET/CT) as an additional or alternative tool to conventional imaging. In particular, we will focus on cancers in which a radioligand therapy with 177lutetium has been attempted, aiming to provide an overview of the possible future theragnostic applications of PSMA.

show abstract

Section: Lung Cancermentioning

confidence: 99%

PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?

Lauri¹,

Chiurchioni²,

Russo³

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…All literature on PSMA tracer uptake by lung cancer derives from accidental findings of lung lesions on PSMA PET/CT scans in patients who received PSMA imaging for their prostate cancer [106][107][108][109][110][111]. The reported SUVmax of lung cancer ranged from 4.8 to 5.6 in lung adenocarcinoma (Table 1).…”

Section: Lung Cancermentioning

confidence: 99%

PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports

Uijen¹,

Derks

Merkx³

et al. 2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

In the past decade, a growing body of literature has reported promising results for prostate-specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate cancer. First clinical studies evaluating the efficacy of [177Lu]Lu-PSMA radioligand therapy (PSMA-RLT) demonstrated favorable results in prostate cancer patients. [177Lu]Lu-PSMA is generally well tolerated due to its limited side effects. While PSMA is highly overexpressed in prostate cancer cells, varying degrees of PSMA expression have been reported in other malignancies as well, particularly in the tumor-associated neovasculature. Hence, it is anticipated that PSMA-RLT could be explored for other solid cancers. Here, we describe the current knowledge of PSMA expression in other solid cancers and define a perspective towards broader clinical implementation of PSMA-RLT. This review focuses specifically on salivary gland cancer, glioblastoma, thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, lung cancer, and breast cancer. An overview of the (pre)clinical data on PSMA immunohistochemistry and PSMA PET/CT imaging is provided and summarized. Furthermore, the first clinical reports of non-prostate cancer patients treated with PSMA-RLT are described.

show abstract

“…The differentiation between primary lung lesions and lung metastases has become a clinical question in prostate cancer patients (Pyka et al, 2016). Conventional imaging such as x-ray, CT, and 18 FDG-PET scans may be used in some cases, but these modalities have some limitations and often need to biopsy for histological confirmation (Chia et al, 2018). PET with 68 Ga-labeled PSMA-HBED-CC is a valuable clinical tool for diagnosis of suspicious lung nodules in PCa patients and to evaluate the specificity of PSMA PET to help in identifying pulmonary PCa metastases.…”

mentioning

confidence: 99%

“…They reported a case with prostate cancer post-prostatectomy, who was identified a lung lesion on PSMA PET/CT scan. But they could not reliably differentiate primary lung lesions from pulmonary metastasis by PSMA PET/CT scans (Chia et al, 2018). In recent research, Damjanovic et al performed the 68 Ga-PSMA-PET imaging of lung metastases in patients with prostate cancer.…”

mentioning

confidence: 99%

The utility of radiolabeled PSMA ligands for tumor imaging

et al. 2021

View full text Add to dashboard Cite

show abstract

Primary Lung Adenocarcinoma With 68Gallium Prostate-Specific Membrane Antigen-PET/CT Scan Avidity in a Patient on Surveillance After Prostatectomy

Cited by 8 publications

References 6 publications

PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?

PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?

PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports

The utility of radiolabeled PSMA ligands for tumor imaging

Contact Info

Product

Resources

About